Nurix Therapeuticsinc Stock Performance
NRIX Stock | USD 14.65 0.81 5.24% |
Nurix TherapeuticsInc holds a performance score of 14 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 3.99, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Nurix TherapeuticsInc will likely underperform. Use Nurix TherapeuticsInc downside variance, as well as the relationship between the daily balance of power and period momentum indicator , to analyze future returns on Nurix TherapeuticsInc.
Risk-Adjusted Performance
14 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Nurix TherapeuticsInc are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak forward indicators, Nurix TherapeuticsInc showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (5.24) | Five Day Return (10.94) | Year To Date Return 43.35 | Ten Year Return (22.94) | All Time Return (22.94) |
1 | Exercise or conversion by Van Houte Hans of 2886 shares of Nurix TherapeuticsInc subject to Rule 16b-3 | 01/30/2024 |
2 | Nurix Therapeutics Inc Stock What Does the Chart Say Tuesday - InvestorsObserver | 02/13/2024 |
3 | Disposition of 6812 shares by Van Houte Hans of Nurix TherapeuticsInc at 10.0151 subject to Rule 16b-3 | 02/16/2024 |
4 | FDA lifts partial hold on Nurix Phase 1 study for NX-2127 | 03/11/2024 |
5 | Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric CancersUsing Targeted P... | 03/25/2024 |
6 | Nurix Therapeutics, Inc. Shares Sold by Public Employees Retirement System of Ohio - Defense World | 03/28/2024 |
7 | Nurix stock gains as Gilead extends RD deal | 04/02/2024 |
8 | Vanda Soars 29.2 percent Is Further Upside Left in the Stock | 04/04/2024 |
9 | Nurix Therapeutics Inc Misses Earnings Predictions But Shows Revenue Growth in Q1 Fiscal 2024 | 04/10/2024 |
10 | Nurix Therapeutics announces proposed public offering | 04/11/2024 |
11 | Nurix Therapeutics prices upsized stock offering to raise 175.0 million | 04/12/2024 |
12 | Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares | 04/16/2024 |
Begin Period Cash Flow | 64.5 M |
Nurix |
Nurix TherapeuticsInc Relative Risk vs. Return Landscape
If you would invest 819.00 in Nurix TherapeuticsInc on January 18, 2024 and sell it today you would earn a total of 646.00 from holding Nurix TherapeuticsInc or generate 78.88% return on investment over 90 days. Nurix TherapeuticsInc is currently generating 1.0913% in daily expected returns and assumes 5.9523% risk (volatility on return distribution) over the 90 days horizon. In different words, 52% of stocks are less volatile than Nurix, and 79% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Nurix TherapeuticsInc Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nurix TherapeuticsInc's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nurix TherapeuticsInc, and traders can use it to determine the average amount a Nurix TherapeuticsInc's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1833
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | NRIX | |||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns |
Estimated Market Risk
5.95 actual daily | 52 52% of assets are less volatile |
Expected Return
1.09 actual daily | 21 79% of assets have higher returns |
Risk-Adjusted Return
0.18 actual daily | 14 86% of assets perform better |
Based on monthly moving average Nurix TherapeuticsInc is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nurix TherapeuticsInc by adding it to a well-diversified portfolio.
Nurix TherapeuticsInc Fundamentals Growth
Nurix Stock prices reflect investors' perceptions of the future prospects and financial health of Nurix TherapeuticsInc, and Nurix TherapeuticsInc fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nurix Stock performance.
Return On Equity | -0.65 | ||||
Return On Asset | -0.29 | ||||
Profit Margin | (1.79) % | ||||
Operating Margin | (2.73) % | ||||
Current Valuation | 545.03 M | ||||
Shares Outstanding | 49.15 M | ||||
Price To Book | 4.88 X | ||||
Price To Sales | 10.17 X | ||||
Revenue | 76.99 M | ||||
Gross Profit | (145.87 M) | ||||
EBITDA | (141.41 M) | ||||
Net Income | (143.95 M) | ||||
Cash And Equivalents | 344.48 M | ||||
Cash Per Share | 7.31 X | ||||
Total Debt | 30.61 M | ||||
Debt To Equity | 0.04 % | ||||
Current Ratio | 5.26 X | ||||
Book Value Per Share | 3.43 X | ||||
Cash Flow From Operations | (81.36 M) | ||||
Earnings Per Share | (2.66) X | ||||
Market Capitalization | 759.87 M | ||||
Total Asset | 364.54 M | ||||
Retained Earnings | (545.2 M) | ||||
Working Capital | 208.54 M | ||||
About Nurix TherapeuticsInc Performance
To evaluate Nurix TherapeuticsInc Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Nurix TherapeuticsInc generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Nurix Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Nurix TherapeuticsInc market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Nurix's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for Next Year | ||
Days Of Inventory On Hand | (42.72) | (40.58) | |
Return On Tangible Assets | (0.45) | (0.48) | |
Return On Capital Employed | (0.50) | (0.53) | |
Return On Assets | (0.45) | (0.48) | |
Return On Equity | (0.83) | (0.78) |
Things to note about Nurix TherapeuticsInc performance evaluation
Checking the ongoing alerts about Nurix TherapeuticsInc for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nurix TherapeuticsInc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Nurix TherapeuticsInc is way too risky over 90 days horizon | |
Nurix TherapeuticsInc appears to be risky and price may revert if volatility continues | |
The company reported the previous year's revenue of 76.99 M. Net Loss for the year was (143.95 M) with loss before overhead, payroll, taxes, and interest of (145.87 M). | |
Nurix TherapeuticsInc currently holds about 344.48 M in cash with (81.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.31. | |
Over 81.0% of the company shares are owned by institutional investors | |
Latest headline from benzinga.com: Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares |
- Analyzing Nurix TherapeuticsInc's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nurix TherapeuticsInc's stock is overvalued or undervalued compared to its peers.
- Examining Nurix TherapeuticsInc's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nurix TherapeuticsInc's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nurix TherapeuticsInc's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nurix TherapeuticsInc's stock. These opinions can provide insight into Nurix TherapeuticsInc's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nurix TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Nurix Stock please use our How to Invest in Nurix TherapeuticsInc guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for Nurix Stock analysis
When running Nurix TherapeuticsInc's price analysis, check to measure Nurix TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix TherapeuticsInc is operating at the current time. Most of Nurix TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Nurix TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix TherapeuticsInc's price. Additionally, you may evaluate how the addition of Nurix TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Transaction History View history of all your transactions and understand their impact on performance | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum |
Is Nurix TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nurix TherapeuticsInc. If investors know Nurix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nurix TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Revenue Per Share 1.483 | Quarterly Revenue Growth 0.307 | Return On Assets (0.29) | Return On Equity (0.65) |
The market value of Nurix TherapeuticsInc is measured differently than its book value, which is the value of Nurix that is recorded on the company's balance sheet. Investors also form their own opinion of Nurix TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Nurix TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nurix TherapeuticsInc's market value can be influenced by many factors that don't directly affect Nurix TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nurix TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nurix TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nurix TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.